Reig Jofre reported a 15% drop in profits in the first quarter of 2024, attributed to the absence of a biosimilar development milestone. However, overall growth...
This week the Catalan pharmaceutical company announced an annual growth of 22% in its income until the third quarter of 2023, which amounted to €237 million....
Reig Jofre registered an EBITDA of €30.4 million in 2022, 11% more than in 2021. Spain concentrated 44% of the group's sales, with a 12% increase...